During the past decade, management of drug resistant chronic hepatitis B (CHB) has been a major issue. A series of new antiviral agents has been developed, which provided new treatment options as well as new resistance issues. Hence, to avoid multidrug resistance, combination of antiviral agents without cross resistance has been recommended. However, combination of the less potent drug did not ...
